StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.72−0.06 (-3.37%)

Close on Nov 18, 2026Market cap $765.32MP/E –Yield –

Lexicon Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lexicon Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$64.99M. For fiscal 2025 it was -$67.85M. The highest annual figure on record is $184.78M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.85M–
FY2024Dec 31, 2024-$178.78M–
FY2023Dec 31, 2023-$161.90M–
FY2022Dec 31, 2022-$88.85M–
FY2021Dec 31, 2021-$87.02M–
FY2020Dec 31, 2020-$142.97M-225.6%
FY2019Dec 31, 2019$113.81M–
FY2018Dec 31, 2018-$148.61M–
FY2017Dec 31, 2017-$185.39M–
FY2016Dec 31, 2016-$175.63M-195.0%
FY2015Dec 31, 2015$184.78M–
FY2014Dec 31, 2014-$75.62M–
FY2013Dec 31, 2013-$91.08M–
FY2012Dec 31, 2012-$94.46M–
FY2011Dec 31, 2011-$87.94M–
FY2010Dec 31, 2010-$82.37M–
FY2009Dec 31, 2009-$89.02M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.19M-154.1%
Q1 FY2026Mar 31, 2026-$14.73M–
Q4 FY2025Dec 31, 2025-$17.23M–
Q3 FY2025Sep 30, 2025-$23.83M–
Q2 FY2025Jun 30, 2025$16.99M–
Q1 FY2025Mar 31, 2025-$43.78M–
Q4 FY2024Dec 31, 2024-$21.49M–
Q3 FY2024Sep 30, 2024-$53.62M–
Q2 FY2024Jun 30, 2024-$48.54M–
Q1 FY2024Mar 31, 2024-$55.13M–
Q4 FY2023Dec 31, 2023-$50.55M–
Q3 FY2023Sep 30, 2023-$41.62M–
Q2 FY2023Jun 30, 2023-$38.12M–
Q1 FY2023Mar 31, 2023-$31.61M–
Q4 FY2022Dec 31, 2022-$21.57M–
Q3 FY2022Sep 30, 2022-$19.44M–
Q2 FY2022Jun 30, 2022-$24.42M–
Q1 FY2022Mar 31, 2022-$23.42M–
Q4 FY2021Dec 31, 2021-$22.83M–
Q3 FY2021Sep 30, 2021-$17.15M–
Q2 FY2021Jun 30, 2021-$21.88M–
Q1 FY2021Mar 31, 2021-$25.16M–
Q4 FY2020Dec 31, 2020-$34.24M–
Q3 FY2020Sep 30, 2020-$40.38M-121.2%
Q2 FY2020Jun 30, 2020-$46.30M–
Q1 FY2020Mar 31, 2020-$22.05M–
Q4 FY2019Dec 31, 2019-$24.37M–
Q3 FY2019Sep 30, 2019$190.70M–
Q2 FY2019Jun 30, 2019-$26.90M–
Q1 FY2019Mar 31, 2019-$25.62M–
Q4 FY2018Dec 31, 2018-$27.13M–
Q3 FY2018Sep 30, 2018-$22.18M–
Q2 FY2018Jun 30, 2018-$52.52M–
Q1 FY2018Mar 31, 2018-$46.78M–
Q4 FY2017Dec 31, 2017-$33.71M–
Q3 FY2017Sep 30, 2017-$33.96M–
Q2 FY2017Jun 30, 2017-$32.23M–
Q1 FY2017Mar 31, 2017-$85.50M–
Q4 FY2016Dec 31, 2016-$48.79M–
Q3 FY2016Sep 30, 2016-$35.22M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?